Ajax Harwood Clinic

Mould and damp-building illness: should I be tested?

Last reviewed 2026-09-23Content v30b0e7dce181
Reference tool — not medical advice. Clinician judgement always required.

Health effects of damp and mouldy buildings

Clinical diagnosis — no single test

Also called: mould exposure, mold exposure, damp building illness, sick building syndrome, mould allergy

Patients ask about mould exposure after noticing visible mould or water damage at home or work, after a musty smell, or after reading about 'mould illness' online. The concern is legitimate: damp and mouldy buildings are genuinely linked to worse respiratory and allergic symptoms. This page covers those real, evidence-based effects; broader claims of multisystem 'mould illness' or 'CIRS' are addressed separately (see the "Mould illness" / "CIRS" (chronic inflammatory response syndrome) section of this page).

Raises suspicion

  • • New or worsening asthma symptoms, allergic rhinitis symptoms, or cough that correlates in time with being in a specific damp or visibly mouldy building
  • • Known water damage, visible mould growth, or a persistent musty odour in the home or workplace
  • • A pre-existing allergic tendency (atopy) or asthma, which increases susceptibility to dampness-related respiratory effects
  • • In a farming, agricultural, or heavy organic-dust occupational setting: fever, cough and shortness of breath hours after exposure, suggesting hypersensitivity pneumonitis (for example, farmer's lung)
  • • In someone with asthma or cystic fibrosis: worsening wheeze with thick mucus plugs or new infiltrates, suggesting allergic bronchopulmonary aspergillosis (ABPA)

Does not raise suspicion

  • • Fatigue, brain fog, joint pain, or other nonspecific multisystem symptoms attributed to a damp building with no respiratory or allergic symptom pattern
  • • Vague 'toxic burden' or general unwellness blamed on mould with no visible dampness, water damage, or musty odour identified

Red flags

  • • Progressive shortness of breath, hemoptysis (coughing blood), or significant breathing difficulty
  • • Fever with cough and shortness of breath after heavy organic-dust or damp-building exposure (possible hypersensitivity pneumonitis)

Who to test

  • New or worsening asthma or allergic rhinitis symptoms linked to a damp or mouldy buildingThis is a clinical diagnosis supported by symptom-exposure correlation, exam, and standard asthma/allergy assessment (spirometry, allergy testing; no TestSelect entry, primary-care- or specialist-directed). See the asthma and allergic-rhinitis tools.
  • Suspected hypersensitivity pneumonitis or ABPASpecialist-directed (respirology/allergy): chest imaging, pulmonary function testing, and specific serologies as directed; no TestSelect entry.

More likely instead

  • • Allergies / hay fever
  • • Asthma
  • • Multisystem fatigue, brain fog, or joint pain without a clear respiratory or allergic pattern is more often explained by chronic-fatigue-syndrome, fibromyalgia, depression, or another cause of fatigue than by building dampness itself
  • • Post-COVID condition (long COVID)

Counselling script

“There's good evidence that damp, mouldy buildings genuinely worsen asthma, allergies, and respiratory symptoms, especially if you're already prone to allergies, so if your symptoms are breathing-related and track with time spent in a specific space, that fits. If you're describing widespread symptoms like fatigue or joint pain without a clear breathing pattern, mould exposure is a less likely explanation, and I'd want to look at other causes alongside addressing the dampness itself.”

Chart snippet (OSCAR-safe plain text)

Concern discussed, not tested

Concern re: health effects of a damp or mouldy building discussed.
Discriminating features: new or worsening asthma or allergic rhinitis symptoms correlating with a specific damp space, visible mould or water damage, occupational organic-dust exposure; absent or present as noted.
Assessment: symptom pattern reviewed against evidence-based dampness-related respiratory and allergic effects.
Plan: standard asthma/allergy assessment as indicated; building remediation discussed; multisystem symptoms without a respiratory pattern investigated separately.
Ref: WHO Guidelines for Indoor Air Quality: Dampness and Mould 2009.
Patient given info page: https://mould.ajaxharwoodclinic.com/patient
Revisit if: new or worsening breathing symptoms, fever with cough and shortness of breath after exposure, or symptoms persisting despite remediation.

Revisit if

  • • New or worsening asthma or allergic rhinitis symptoms
  • • Fever, cough, or shortness of breath after heavy dust or damp-building exposure
  • • Progressive breathing difficulty or coughing blood
  • • Symptoms persisting despite building remediation: reassess for another cause

References

  1. 1. World Health Organization. WHO Guidelines for Indoor Air Quality: Dampness and Mould (2009)— older guidelineOccupants of damp or mouldy buildings are at increased risk of respiratory symptoms, respiratory infections, and exacerbation of asthma, with some evidence for increased allergic rhinitis risk and clinical evidence linking mould/dampness-related microbial agents to hypersensitivity pneumonitis and allergic fungal sinusitis
Evidence notes

Tag B: damp-building respiratory and allergic effects are a real, clinically diagnosed picture (symptom-exposure correlation plus standard asthma/allergy assessment), with no single confirmatory test, so no A tag; not borderline as a B tag, though the reviewer should confirm the tag given docs/open-questions.md item 4's open structural question. This record is this batch's draft answer to that open question: it makes 'mould.' anchor on this real, evidence-based condition (asthma/allergy exacerbation, and rarely hypersensitivity pneumonitis/ABPA) rather than being a page with only C-tagged content, with '"Mould illness" / "CIRS" (chronic inflammatory response syndrome)' hosted inside it as the C label, mirroring the mthfr. precedent. This is a proposal pending Dr. Yu's sign-off, not a settled decision. [1] is flagged older_than_10y (2009); its core respiratory/allergic findings were not contradicted by anything found this session, but a more recent synthesis (e.g. an updated systematic review) was not independently located and would strengthen this page. Resolved 2026-09-23: Dr. Yu approved the mould. structure and tag B (decisions 4 and 10).

Popular labels: what they mean

"Mould illness" / "CIRS" (chronic inflammatory response syndrome)

Not a recognized medical diagnosis

Also called: mould illness, mold illness, mold toxicity, CIRS, chronic inflammatory response syndrome, biotoxin illness, mycotoxin illness

Patients encounter 'mould illness,' 'CIRS,' or 'biotoxin illness' from an ND, a specialty practitioner, or online communities, usually as an explanation for a broad, multisystem picture of fatigue, brain fog, joint pain, and other symptoms attributed to past or current mould exposure, sometimes supported by a urine mycotoxin test or a proprietary symptom-and-biomarker questionnaire.

Does not raise suspicion

  • • Fatigue, brain fog, joint pain, or other multisystem symptoms attributed to a damp building or 'mould exposure' with no respiratory or allergic symptom pattern: these symptoms are real, but the mould/CIRS explanation for them is not established
  • • A positive urine mycotoxin test used to diagnose 'mould illness': mycotoxins appear in the urine of healthy people from ordinary dietary sources, and no validated urine mycotoxin level predicts disease
  • • A proprietary symptom checklist, visual contrast sensitivity score, or biomarker panel used to diagnose CIRS

Red flags

  • • None specific to this label. If there is a genuine respiratory or allergic reaction to a damp building, see the main mould page. If symptoms suggest another serious condition, that condition is assessed directly.

Who to test

  • Anyone with, or considering, urine mycotoxin testing to diagnose 'mould illness' or CIRSNo validated test exists for this label. Start with a visual inspection of the building for water damage or visible mould, address any respiratory or allergic symptoms directly (see the main mould page), and investigate multisystem symptoms on their own merits.

More likely instead

  • • ME/CFS
  • • Fibromyalgia
  • • Post-COVID condition (long COVID)
  • • Depression
  • • Real, evidence-based respiratory or allergic effects of a damp building (see the main mould page), when the symptom pattern is respiratory or allergic rather than multisystem

Counselling script

“I understand mould has been raised as an explanation for how you're feeling, and your symptoms are real, but urine mycotoxin testing isn't validated. Public health authorities have documented real harm from acting on results, including costly building testing and unnecessary treatment. If you have breathing or allergy symptoms tied to a damp space, that's worth addressing directly. For the wider symptoms you're describing, I'd rather look for a specific, treatable cause than test for mould toxins.”

Chart snippet (OSCAR-safe plain text)

Concern discussed, not tested

Concern re: 'mould illness' / CIRS discussed, raised by patient or practitioner, often with a urine mycotoxin result.
Assessment: urine mycotoxin testing and CIRS symptom/biomarker panels are not validated diagnostic tools. Symptoms discussed and validated.
Plan: mycotoxin testing not ordered or acted on; respiratory or allergic symptoms assessed separately if present; multisystem symptoms investigated on their own merits.
Ref: CDC MMWR notes from the field on unvalidated urine mycotoxin testing 2015.
Patient given info page: https://mould.ajaxharwoodclinic.com/patient#"Mould illness" / "CIRS" (chronic inflammatory response syndrome)
Revisit if: a respiratory or allergic symptom pattern tied to a damp building develops (see the main mould page), or a specific, treatable cause for multisystem symptoms is identified.

Revisit if

  • • New or worsening respiratory or allergic symptoms tied to a damp building: see the main mould page
  • • Symptoms significantly affecting daily function despite reassurance: reassess for chronic fatigue syndrome, fibromyalgia, depression, or another treatable cause

References

  1. 1. US Centers for Disease Control and Prevention (MMWR). Notes from the Field: Use of Unvalidated Urine Mycotoxin Tests for the Clinical Diagnosis of Illness — United States, 2014 (2015)There is no FDA-approved test for mycotoxins in human urine and no established, validated urine mycotoxin level that predicts disease; acting on a positive result led to documented harm in an investigated case
Evidence notes

Tag C: no professional-society statement affirmatively validating CIRS diagnostic criteria (the proprietary Shoemaker biomarker panel and visual contrast sensitivity testing) was located this session; the practitioner-authored 'Surviving Mold' literature promoting these criteria is not independent evidence and was not used as a source. This is the honest gap called for when no credible validating or rejecting professional-society source exists: rather than overstate the case with a source that doesn't really say what's needed, this record leans on [1] (documented harm from acting on unvalidated urine mycotoxin results) and on [World Health Organization 2009], cited on the host mould page, which finds sufficient evidence only for respiratory and allergic effects of damp buildings, not for the multisystem 'biotoxin' model CIRS proposes. The Institute of Medicine's 2004 'Damp Indoor Spaces and Health' report was identified as a further, similarly-scoped source in this session's research but was not independently fetched and verified this session, so it is not cited; a reviewer wanting a second anchor for 'insufficient evidence beyond respiratory/allergic effects' could add it. Host is 'mould' per the C-label hosting convention and this batch's mould. structural proposal (see Health effects of damp and mouldy buildings's evidence_notes).

General clinical reference for Ajax Harwood Clinic. Not medical advice, and not a substitute for individualized clinical assessment.